Patents by Inventor David Waterhouse

David Waterhouse has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • Publication number: 20050181514
    Abstract: Methods for enhancing detection by mass spectroscopy (MS) and/or chromatographic separability of carbonyl-containing compounds such as steroids are disclosed. Reaction of a carbonyl compound with a sulfonhydrazide compound provides a sulfonhydrazone with enhanced ionization efficiency during the electrospray ionization process. In a particularly disclosed embodiment, derivatization of catechol estrogens with p-toluenesulfonhydrazide enhances both detection by atmospheric pressure ionization-MS (API-MS), such as electron spray ionization-MS (ESI-MS) and separation by liquid chromatography (such as HPLC) under reverse phase conditions. In yet other embodiments, the sulfonhydrazone is further reacted with a sulfonyl halide under alkaline conditions to derivatize hydroxyl groups in the compound. Prior formation of the sulfonhydrazide derivative protects the carbonyl bond of the compound during subsequent alkaline reaction with the sulfonyl halide.
    Type: Application
    Filed: April 15, 2003
    Publication date: August 18, 2005
    Inventors: Xia Xu, Regina Ziegler, David Waterhouse, Joseph Saavedra, Larry Keefer
  • Publication number: 20050148566
    Abstract: The present invention provides compound of the formula (I): in which at least two of R1, R2, R3, R4, R5, and R6 are N2O2M and related compounds, substrates, compositions, and methods of using such compounds and compositions to treat biological disorders in which a polyphasic release of nitric oxide would be beneficial.
    Type: Application
    Filed: November 5, 2004
    Publication date: July 7, 2005
    Applicant: The Government of the USA, as Rep. by the Secretary, Dept. of Health & Human Services
    Inventors: David Waterhouse, Preeya Kapur, Larry Keefer, Joseph Hrabie, Frank Rosa
  • Patent number: 5714667
    Abstract: Disclosed is a mouse in which expression of the gene encoding the CTLA-4 receptor is suppressed. Also disclosed is a nucleic acid construct useful in preparing such a mouse, and a cell line containing such construct.
    Type: Grant
    Filed: November 6, 1995
    Date of Patent: February 3, 1998
    Assignee: Amgen Canada Inc.
    Inventors: Paul David Waterhouse, Tak Wah Mak